Skip to main content

Roche's Tecentriq Demonstrates Survival Benefit in PD-L1 High NSCLC

NEW YORK – In an interim analysis of the Phase III IMpower110 study, advanced non-small cell lung cancer patients receiving first-line treatment with atezolizumab (Tecentriq) and high PD-L1 expression lived longer compared to those on chemotherapy, according to Roche subsidiary Genentech.

The drugmaker will present data from this trial at an upcoming meeting and submit this data to the US Food and Drug Administration and the European Medicines Agency.

The IMpower110 study randomized 555 people to receive atezolizumab monotherapy or chemotherapy with cisplatin or carboplatin, combined with gemcitabine or pemetrexed. Researchers are investigating how these treatments impact overall survival according patients' PD-L1 status, as well as progression-free survival, objective response rate, and duration of response. Patients in the study also couldn't have ALK or EGFR mutations. 

"These findings reinforce the potential of [atezolizumab] to play an important role in the treatment of multiple forms of lung cancer, and we look forward to discussing these data with health authorities," Sandra Horning, Genentech Chief Medical Officer, said in a statement.